Stereotaxis will announce Q4 2024 financial results on March 3, 2025, with a conference call at 8:30 a.m. ET.
Quiver AI Summary
Stereotaxis, a leader in surgical robotics for minimally invasive endovascular procedures, has announced that it will release its financial results for the fourth quarter and full year of 2024 on March 3, 2025, prior to the U.S. markets opening. The company will host a conference call and webcast at 8:30 a.m. ET that same day to discuss these results and other corporate developments. Participants can dial in using specific phone numbers provided or access a webcast through Stereotaxis' investor relations website. Additionally, a replay of the call will be available for a month after the event. Stereotaxis is committed to enhancing patient care and the operational capabilities of interventional laboratories through its innovative robotic systems, which have already benefited over 150,000 patients globally.
Potential Positives
- Stereotaxis will release its financial results for Q4 and full year 2024 on March 3, 2025, indicating transparency and commitment to keeping investors informed.
- The upcoming conference call and webcast will provide a platform for discussing corporate developments, suggesting proactive engagement with stakeholders.
- Stereotaxis' technology has been used to treat over 150,000 patients globally, highlighting the significant impact and trust in its innovative surgical robotics solutions.
Potential Negatives
- The announcement of the financial results release indicates that the company may be experiencing heightened scrutiny regarding its financial performance, particularly if investors have concerns leading up to the announcement.
FAQ
When will Stereotaxis release its 2024 financial results?
Stereotaxis will release its financial results on Monday, March 3, 2025, before U.S. market open.
What time is the Stereotaxis conference call?
The conference call is scheduled for 8:30 a.m. ET on March 3, 2025.
How can I access the Stereotaxis conference call?
To access the call, dial 800-715-9871 (US) or 1-646-307-1963 (International) with pass code 1983976.
Where can I find the Stereotaxis webcast?
The live and replay webcast can be accessed on the investor relations section of Stereotaxis’ website.
Is there a replay available for the Stereotaxis call?
A phone replay will be available for one month, starting approximately four hours after the call ends.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STXS Insider Trading Activity
$STXS insiders have traded $STXS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STXS stock by insiders over the last 6 months:
- PAUL J ISAAC has made 3 purchases buying 9,349 shares for an estimated $17,707 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STXS Hedge Fund Activity
We have seen 43 institutional investors add shares of $STXS stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARCHON CAPITAL MANAGEMENT LLC removed 314,183 shares (-19.7%) from their portfolio in Q3 2024, for an estimated $640,933
- NORTHERN TRUST CORP added 311,589 shares (+204.4%) to their portfolio in Q3 2024, for an estimated $635,641
- BLACKROCK, INC. added 282,774 shares (+8.0%) to their portfolio in Q3 2024, for an estimated $576,858
- WARBERG ASSET MANAGEMENT LLC removed 258,302 shares (-56.0%) from their portfolio in Q3 2024, for an estimated $526,936
- TRAYNOR CAPITAL MANAGEMENT, INC. added 160,509 shares (+inf%) to their portfolio in Q4 2024, for an estimated $365,960
- RENAISSANCE TECHNOLOGIES LLC removed 126,500 shares (-25.9%) from their portfolio in Q3 2024, for an estimated $258,060
- CERITY PARTNERS LLC added 124,011 shares (+inf%) to their portfolio in Q3 2024, for an estimated $252,982
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company’s results and corporate developments.
What: | Stereotaxis fourth quarter and full year 2024 financial results conference call |
When: | Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT) |
Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 1983976. |
Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/ . |
Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here . |
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com .
Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
[email protected]